Partnership between Bristol Meyers Squibb and AbbVie aims to evaluate the Combination of Rova-T plus Opdivo and Opdivo plus Yervoy Regimen
Bristol Meyers Squibb and AbbVie have undergone an oncology clinical collaboration to develop a treatment option for patients with relapsed extensive-stage small cell lung cancer (SCLC). The collaboration is aimed to evaluate safety, tolerability and efficacy of Bristol-Myers Squibb’s Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) in combination with AbbVie’s investigational biomarker-specific antibody drug Rova-T (rovalpituuzumab tesirine) in a phase I/II clinical trial,. The combination will be tested to promote targeted cell...
